Previous clinical trials confirmed the crosstalk between several apoptotic markers (Bcl-2, Bax, and Fas), with a typical algorithm for increased pro-apoptotic (and/or decreased anti-apoptotic) activity that correlates to the severity of depressive disorder [5], as well as to the outcomes of treatment with antidepressants [6]. This evidence concerns the gene BAX and depressive disorder.